A researcher in a lab looking at a tablet.

ALK+ Blog/News

  • Hope for ALK+ NSCLC Patients

    It’s important that we generate our own hope throughout the challenges and difficulties of ALK+ NSCLC.  Oh yes, there is plenty to be hopeful about on the research and treatment

    Read More

  • A scientist in a lab looking through a microscope and writing on a clipboard.

    Update on Clinical Trials currently recruiting for ALK-positive lung cancer

    A new ALK inhibitor starts its clinical trials this month! TPX-0131 is an TKI ALK inhibitor designed to overcome multiple ALK resistance mutations. This first-in-human trial for ALK-positive lung cancer

    Read More

  • Real World Data in Medical Research

    What is real world data vs. on-paper data?  Scientists create experiments in laboratories and present the best data they can in published papers for everyone to share.  That’s paper data. 

    Read More

  • Patient Spotlight: Milestones after a stage IV diagnosis

    Featured: In this newsletter, we are celebrating milestones. A cancer diagnosis (even at stage IV), while devastating, can often open up new doors and lead patients to a new calling

    Read More

  • ,

    Dr. Justin Gainor & Dr. Aaron Hata join ALKtALK

    Dr. Justin Gainor, MD Director of Center for Thoracic Cancers & Director of Targeted Immunotherapy at Massachusetts General Hospital, Boston Assistant Professor of Medicine at Harvard Medical School “It’s great

    Read More

  • Hydration Dos & Don’ts

    Hydration talk.   When I am sick, I always seek out a bowl of “chicken noodle soup.” In every culture, there’s always something soothing, whether it is a stew, soup, or

    Read More

  • ,

    Dr. Mark Awad & Dr. Roberto Chiarle join ALKtALK

    Mark Awad, MD, PhD  Clinical Director, Thoracic Oncology Treatment Center Assistant Professor of Medicine, Harvard Medical School I hope everyone is safe, warm, and healthy tonight. I am the Clinical

    Read More

  • Ensartinib: the unknown TKI

    Ensartinib (x396) is a medicine made by Xcovery, a biotech company based in Florida. It works closely with another company called Betta Pharmaceuticals in China for many of its trials.

    Read More

  • ,

    Dr. Jessica Lin and Dr. Ibiayi Dagogo-Jack join ALKtALK

    Dr. Jessica Lin Attending physician, Hematology/Oncology, Massachusetts General Hospital Instructor, Medicine, Harvard Medical School Dr. Lin: I first began interested in oncology in my undergraduate years. I started out as

    Read More

  • Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations

    An updated review of the most current targeted therapies in NSCLC (non-small cell lung cancer) by targetable mutation. Dr. David Konig, Dr. Spasenija S. Prince, and Dr. Sacha I Rothschild

    Read More

  • Fundraiser Spotlight Series

    EDITOR’S NOTE: Starting with this newsletter, we are launching a new “Fundraiser Spotlight Series”, featuring some of our top fundraisers in recent years. The idea is for members to get

    Read More

  • ,

    Dr. Christine Lovly joins ALKtALK

    Editor’s Note: A special thanks to Marc Rosenzweig for creating and scheduling the ALKtALK programs. Alice Chou graciously committed her time to transcribe thisALKtALK with Dr. Lovly so that it

    Read More